Donor-specific and -nonspecific HLA antibodies and outcome post lung transplantation
Evidence level: retrospective single-centre cohort; abstract-only
A cohort study of 362 patients linking donor-specific HLA antibodies, especially persistent ones, to shorter CLAD-free survival and to restrictive CLAD.
As of . Primary source: Publisher record via DOI.
Summary
The study assessed the association between HLA antibodies and CLAD-free and graft survival in 362 lung transplant patients. According to the abstract, 61 patients (17 percent) developed donor-specific antibodies (DSAs), mostly against HLA-DQ, and both persistent and transient DSAs were associated with shorter CLAD-free survival, while only persistent DSAs were associated with worse graft survival. The abstract attributes this probably to the higher incidence of restrictive CLAD, and the authors suggest an overlap between antibody-mediated rejection and restrictive CLAD that needs further investigation. Non-donor-specific and pre-transplant HLA antibodies had no effect on outcome. The study is observational and the centre is not named in the abstract.
Details
- doi
- 10.1183/13993003.01248-2017
- pmid
- 29146602
- authors
- Verleden SE, Vanaudenaerde BM, Emonds MP, Van Raemdonck D, Neyrinck AP, Verleden GM, Vos R
- journal
- European Respiratory Journal
- year
- 2017
- articleNumber
- 1701248
- volume
- 50
- issue
- 5
Sources and links
- Publisher record via DOI (primary)
- PubMed 29146602
Related
Links from this record
- supports: Humoral (antibody-mediated) alloimmunity
- associates with: Restrictive allograft syndrome (RAS)
Linked from (derived)
Known gaps in this record
- full text not read (abstract only)
- funding statement and grant numbers
- author affiliations
- centre or centres not stated in the abstract
Information resource only. Not medical advice. Not a substitute for the care of the patient's transplant team.